1449.1000 -83.00 (-5.42%)
NSE Nov 21, 2025 15:31 PM
Volume: 145.9K
 

1449.10
-5.42%
ICICI Securities Limited
Tatva Chintan’s Q2FY23 revenue fell 27.1% YoY and EBITDA plunged 68.9% YoY due
to lower SDA sales, which seems very disappointing, but we believe this situation is
transitory.
Tatva Chintan Pharma Chem Ltd. is trading above all available SMAs
More from Tatva Chintan Pharma Chem Ltd.
Recommended